Guggenheim raised the firm’s price target on Axsome Therapeutics (AXSM) to $195 from $135 and keeps a Buy rating on the shares after updating the firm’s model following Axsome’s Q4 report.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics Sees Robust Growth and Strategic Progress
- Axsome Therapeutics Inc. Earnings Report: Is it a Beat?
- Axsome Therapeutics’ Earnings Call: Growth Amid Challenges
- Axsome Therapeutics: Strong Performance and Promising Pipeline Justify Buy Rating
- Axsome Therapeutics reports Q4 EPS ($1.54), consensus ($1.00)